3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
416
Lymphoma
406
Lymphoma, Non-Hodgkin
344
Leukemia, Lymphocytic, Chronic, B-Cell
313
Lymphoma, Follicular
301
Lymphoma, Mantle-Cell
226
Lymphoma, B-Cell, Marginal Zone
161
Lymphoma, B-Cell
112
Leukemia
112
Burkitt Lymphoma
110
Waldenstrom Macroglobulinemia
99
Precursor Cell Lymphoblastic Leukemia-Lymphoma
90
Recurrence
82
Hodgkin Disease
60
Lymphoma, Large-Cell, Immunoblastic
57
Neoplasms
33
Lymphoma, Large-Cell, Anaplastic
26
Myelodysplastic Syndromes
24
Leukemia, Myeloid, Acute
24
Multiple Myeloma
21
Dendritic Cell Sarcoma, Interdigitating
19
Intraocular Lymphoma
17
Leukemia, Prolymphocytic
15
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
14
Lymphoma, T-Cell
14
Hematologic Neoplasms
13
Lymphoproliferative Disorders
12
Leukemia, Hairy Cell
11
Leukemia, B-Cell
11
Hematologic Diseases
11
Interventions
duvelisib
3
parsaclisib
1
obinutuzumab
1
liposomal doxorubicin
1
chiauranib
1
Taxes
1
Rituximab
1
Panobinostat
1
Paclitaxel
1
Lomustine
1
Irinotecan
1
Gemcitabine
1
Everolimus
1
Doxorubicin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
Rituximab
×
Lymphoid
×
Clear all
NCT02204982
2023-09-28
DYNAMO + R
SecuraBio
Phase 3
Terminated
13 enrolled
10 charts
1 FDA